# Cerebral Cavernous Malformations With Dynamic and Progressive Course

Correlation Study With Vascular Endothelial Growth Factor

Keun-Hwa Jung, MD; Kon Chu, MD; Sang-Wuk Jeong, MD; Hee-Kwon Park, MD; Hee-Joon Bae, MD; Byung-Woo Yoon, MD, PhD

**Background:** Cerebral cavernous malformations (CCMs) are reported to exhibit a wide range of dynamic patterns including growth, regression, and de novo formation, which generally show slow and steady courses. Although the pathogenesis of CCMs is not well known, vascular endothelial growth factor (VEGF) has been suggested as a possible mediating factor.

**Objectives:** To report CCMs showing rapid progression over a short period and to investigate these biological characteristics.

**Design:** Experimental study.

**Setting:** Tertiary referral center, neurology department.

**Patient:** A 40-year-old man was admitted because of a left-sided numbness, vertigo, and ataxia, which were attributed to a pontine hemorrhage. He had experienced a left-sided weakness 6 months before admission, and thereafter had complained of intermittent headache. Serial brain magnetic resonance images showed multiple intracerebral microhemorrhages throughout the cerebral hemi-

spheres. A biopsy of the lesion confirmed the diagnosis of CCM.

**Main Outcome Measures:** We investigated the expression of VEGF by immunohistochemistry of the biopsy specimen. Dynamic patterns of CCMs, obtained with spin-echo magnetic resonance images with gradient-echo sequences, were compared with serial serum VEGF concentrations, determined by enzyme-linked immunosorbent assay.

**Results:** Immunohistochemistry of the specimen displayed increased VEGF expression. Serial magnetic resonance images during 7 months showed dynamic signal changes of the preexisting lesions and 15 de novo formations in many cortices. The VEGF level in serum increased during this dynamic period and became normal during the steady and resolving stages.

**Conclusions:** Cerebral cavernous malformations can be progressively deteriorating. The endothelial proliferation induced by VEGF is likely to be an important aspect of the pathogenetic mechanisms of CCMs.

Arch Neurol. 2003;60:1613-1618

From the Department of Neurology and Clinical Research Institute, Seoul National University Hospital, Seoul (Drs Jung, Chu, Park, and Yoon), and Departments of Neurology, Eulji Medical Center, Seoul (Dr Bae), and Ilsan Paik Hospital, Inje University, Ilsan (Dr Jeong), South Korea. EREBRAL CAVERNOUS malformations (CCMs) are well-circumscribed lesions that consist of closely packed, enlarged,

capillarylike vessels, without intervening parenchyma.<sup>1</sup> Although CCMs have been generally regarded as congenital lesions that arise as a result of disordered mesodermal differentiation during the early stages of embryogenesis,<sup>2,3</sup> recent studies have documented the growth and de novo appearance of sporadic or familial CCMs.<sup>4-9</sup>

However, the molecular mechanisms underlying the genesis and maintenance of these abnormal vascular phenotypes are not well known. Several studies have supported the notion that 2 main systems of angiogenesis, vascular endothelial growth factors (VEGFs) and their endothelial cell– specific protein tyrosine kinase receptors (flk-1, flt-1), mediate various facets of blood vessel formation during vascular response to injury and disease.<sup>10,11</sup>

We studied an unusual sporadic case of multiple CCMs that showed an aggressive behavior, and we investigated the biological activities of these CCMs to elucidate the mechanisms underlying their growth and de novo genesis.

**REPORT OF A CASE** 

A 40-year-old man was admitted because of sudden vertigo, numbness, and leftsided ataxia. Six months before admission, he had suffered an intracerebral hemorrhage (ICH) with left-sided weakness. Magnetic resonance (MR) imaging of the brain at the time of this previous admis-



Figure 1. Representation of the dynamic signal changes of cerebral cavernous malformations (A-C, first event, initial magnetic resonance imaging; D-F, 6 months after the initial magnetic resonance imaging): Type III lesion (A) in the left anterior cerebellum changed to type I (D), and type I lesion (B) in the right frontal cortex changed to type III (E, arrow indicates the lesion studied by biopsy). Type II lesion (F) in the right pons had newly developed.

sion showed multiple intracerebral microhemorrhages throughout the cerebral hemispheres, suggestive of CCMs, although he had no relevant family history. He had also complained of a general weakness and intermittent headache during the preceding 6 months. He had no history of hypertension, dyslipidemia, trauma, seizure, or diabetes mellitus.

Brain MR images on the second admission showed dynamic signal changes and 12 de novo lesions, including a newly developed right pontine hemorrhage (**Figure 1** and **Figure 2**). On the 30th hospital day of the second admission, dysarthria, hoarseness, diplopia, and left-sided weakness developed, and follow-up MR images showed the enlarged pontine lesion and the presence of 3 de novo lesions. Investigations for coagulation abnormalities, systemic vasculitis, and cardioembolic sources showed no remarkable findings. The cerebral angiogram was also normal. The patient was treated with intravenous methylprednisolone acetate at 1 g/d for 5 days from the 30th hospital day, followed by oral prednisolone acetate (60 mg). His neurologic symptoms improved steadily, and the oral prednisolone was slowly tapered over 4 weeks.

On the 50th hospital day, to clarify the cause of the highly dynamic, cerebral lesions, brain biopsy was performed stereotactically on the right frontal lesion. The patient was discharged in a much improved state on the 60th hospital day. One month after discharge, a follow-up brain MR image showed no signal changes or de novo formations. He remained free of recurrence of the disease during a 7-month follow-up period.

#### METHODS

## MR IMAGING DATA ACQUISITION AND ANALYSIS

We performed MR imaging studies on a 1.5-T MR unit (Signa Horizon, Echospeed; General Electric Medical Systems, Waukesha, Wis) with echoplanar imaging, as described in previous studies from our group.<sup>12,13</sup> The standardized MR imaging protocol consisted of fast spin-echo, T2-weighted images (repetition time/echo time, 4200/112 milliseconds; field of view, 21 × 21 cm; matrix,  $256 \times 192$ ; and slice thickness, 5 mm with 1.5-mm gap) and T2\*-weighted gradient-echo sequences (repetition time/echo time, 200-500/15 milliseconds; flip angle, 20°; number of excitations, 2; slice thickness, 1.4 mm; and gap width, 0.7 mm).

The lesions were classified as previously described<sup>14</sup>: type I: a high-signal core on T1-weighted images and a high- or lowsignal core with a low-signal rim on T2-weighted images; type II: a reticular mixed-signal core on T1- and T2-weighted images and a low-signal rim on T2-weighted images; type III: homogeneously isointense or low-signal area on T1- and T2weighted images; and type IV: seen poorly or not at all on spinecho images and focally with a decreased signal on gradientecho images. In the present study, we analyzed the dynamic changes of the different signal lesions and de novo CCM formation on serial brain MR images.

## HISTOLOGIC PROCESSING OF THE BIOPSY TISSUE

Tissue specimens were fixed in 4% formalin and embedded in paraffin blocks. Sequential 6-µm sections cut from paraffin blocks were deparaffinized in xylene, rehydrated, and prepared for routine histologic examination (hematoxylin-eosin



Figure 2. Representative de novo formations of cerebral cavernous malformations. A and D are images obtained at the time of the first event. Similar images were obtained 6 months (B and E) and 7 months (C and F) after the initial imaging.

staining), immunohistochemical studies for VEGF, and Congo red staining. After being rinsed in phosphate-buffered saline, the tissue on the slide was heated in 50mM L-glycinehydrochloric acid buffer (pH 3.5) containing 0.01% wt/vol EDTA at 95°C for 5 minutes, as a pretreatment for VEGF. The specimen then was incubated with a 1:800 dilution of primary rabbit anti-VEGF polyclonal antibody (NeoMarkers; Lab Vision Corporation, Fremont, Calif) for 48 hours at 4°C. After washing with 0.5M Tris-buffered saline, the section was incubated with a 1:200 dilution of the secondary antibody, Cy3conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories, Inc, West Grove, Pa). Immunofluorescent labeling was analyzed with a laser confocal scanning microscope (Nikon PCM-2000; Nikon Inc, Melville, NY). Alternating sections were stained in a similar way but without primary antibody. Immunoreactivity to VEGF was not detected in these sections. Congo red staining was analyzed by means of a polarizing microscope.

#### ENZYME-LINKED IMMUNOSORBENT ASSAY

To determine VEGF concentrations in serum, we used a commercially available sandwich enzyme-linked immunosorbent assay kit, with elevated levels defined as greater than 55 pg/mg on the basis of normal population results (Quantikine Kit; R&D Systems Inc, Minneapolis, Minn). Among the isomers of VEGF, VEGF<sub>164</sub> was selected because it is the main isomer expressed in cerebrovascular disorders.<sup>15-18</sup> Ratios of VEGF protein to total protein concentration were calculated and expressed as picograms per milligram of total protein. Intra-assay and interassay variations were within the range provided by the manufacturer. The VEGF concentration in serum was determined repeatedly during the clinical deterioration and regression, ie, at onset (current admission), during the deterioration period, at steady state, and during improvement. The VEGF levels were also compared with those of age-matched, healthy controls (n=20) and subjects with hypertensive pontine ICH (n=8, 3)days after onset).

## RESULTS

## MR IMAGING ANALYSIS

By MR imaging analysis, the initial MR images at the first admission showed 13 lesions of various types (1 lesion of type I, 7 of type III, and 5 of type IV). Six months after the first admission, these lesions had changed dramatically and the total number of lesions had increased to 25. These newly developed lesions were composed of 2 of type II, 4 of type III, and 6 lesions of type IV. Seven

(REPRINTED) ARCH NEUROL/VOL 60, NOV 2003 WWW.ARCHNEUROL.COM 1615



Figure 3. Timetable representing dynamic signal changes in serial follow-up magnetic resonance (MR) imaging (A) and changes in vascular endothelial growth factor (VEGF) concentration in serum (B) over 9 months (0 month, first event; 6 months, second event or current admission; 7 months, progression; 8 months, steady period; 9 months, improvement period).



Figure 4. A and B, A 1-cm lesion in the frontal lobe of a 40-year-old man, compatible with cerebral cavernous malformation, composed of thin-walled dilated vascular channels with fibrotic walls and with little or no intervening brain parenchyma (hematoxylin-eosin, original magnification ×40 [A]; ×200 [B]). C, Results of immunofluorescence labeling for vascular endothelial growth factor in the same section.

months after the initial MR imaging, with clinical deterioration, the lesion number increased to 28 and all the newly developed lesions were of type IV. After prednisolone treatment (9 months after the initial MR imaging), no new lesion was detected and further morphologic changes were not observed. The timetable for these events is illustrated in **Figure 3**.

## PATHOLOGICAL STUDY

A biopsy was performed of the type III lesion in the right frontal area on the 50th hospital day (Figure 1E). On pathological examination, closely apposed dilated vascular channels with fibrotic walls were observed and little or no intervening brain parenchyma was seen. Some hemosiderin deposits were observed in the surrounding brain tissue (Figure 4A). The capillarylike vessel walls were lined by a single layer of endothelium and collagenous adventitia (Figure 4B). Routine pathological examination demonstrated the typical findings of CCMs. Immunohistochemical study showed significantly increased VEGF expression in the lesion (Figure 4C), in contrast to the rare expression in normal brain tissue (data not shown). There were no amorphous materials, which give apple-green birefringence on polarizing microscopy (data not shown).

## MEASUREMENT OF SERUM VEGF LEVELS

The VEGF concentration in serum was increased from 228.6 pg/mg (at admission) to 419.4 pg/mg (at 4 weeks) during the dynamic period (healthy control group [n=20], 59.3 pg/mg; subjects with hypertensive pontine ICH, 3 days after onset [n=8], 78.4 pg/mg). Despite this dramatic increase in the VEGF concentration, serum VEGF levels during the steady and improving phases became almost normal (8 weeks, 54.2 pg/mg; 12 weeks, 71.8 pg/mg). The timetable for these results is also illustrated in Figure 3.

#### COMMENT

Our patient had recurrent strokelike episodes and intermittent headaches without a relevant family history, and the diagnosis of CCMs in this patient was pathologically confirmed. Remarkably, serial examinations of brain MR images showed very dynamic changes in the signal intensities of multiple lesions, and 15 de novo lesions developed during 7 months. An immunohistochemical study showed significantly increased VEGF expression in the type III lesion studied by biopsy. The progression of CCMs on brain MR imaging correlated well with higher VEGF levels. Of note, elevated VEGF levels and disease pro-

(REPRINTED) ARCH NEUROL/VOL 60, NOV 2003 WWW.ARCHNEUROL.COM 1616

Source	Form	No. of Cases (N = 670)	Study Period, mo	Hemorrhage Rate, %/Patient-year	De Novo Lesions	
					No./Patient-year	Туре
Del Curling et al, <sup>24</sup> 1991	Sporadic or familial	32	46	0.25		
Robinson et al,22 1991	Sporadic	66	26	1.5		
Zambramski et al, <sup>14</sup> 1994	Familial	31	26	13	0.4	111
Aiba et al, <sup>26</sup> 1995	Sporadic or familial	110	56	0.39		
Kondziolka et al, <sup>27</sup> 1995	Sporadic or familial	122	34	2.6		
Kim et al, <sup>28</sup> 1997	Sporadic or familial	62	22	2.3		
Porter et al. <sup>30</sup> 1997	Sporadic or familial	173	46	4.2		
Labauge et al, <sup>1</sup> 2000	Familial	40	38	11	0.2	111
Labauge et al, <sup>31</sup> 2001	Familial	33	25	4.3	0.4	IV
Present study	Sporadic	1	7	5.1 events/patient-v	25.7 (15/7 mo)	.    .

gression were altered by the administration of predniso-lone.

Clinical presentation of CCMs is characterized by ICH, seizures, and focal neurologic deficits, including nonspecific symptoms such as headache, vertigo, and tinnitus, but most of the lesions remain asymptomatic.<sup>19,20</sup> The CCMs range in size from grossly invisible to the involvement of a large part of an entire hemisphere, and they may be single or multiple lesions and sporadic or familial.<sup>21</sup> Traditionally, CCMs have been presumed to be congenital lesions that arise during the early embryonic stage, and that grow according to malformative mechanisms and blood-flow changes.<sup>22</sup> More recently, however, dynamic activities including enlargement, regression, and de novo formation have been described in both the familial and sporadic forms of CCM (Table).<sup>1,14,23-31</sup> The possibility that the number of lesions might increase with age has been also documented.<sup>20,32</sup> Reportedly, the annual risk of hemorrhage in sporadic or familial CCMs has been estimated at 0.25% to 13% per patient-year, and de novo formations appear with an incidence of 0.2 to 0.4 lesion per year. Moreover, it might be expected that the rates of hemorrhage and of de novo formation of CCMs in the actual population lie between the lowest retrospective rates and the highest prospective rates. However, the CCMs in our patient showed dynamic features well beyond this type of estimation (Table).

The underlying mechanisms inherent to the genesis and maintenance of these abnormal vascular phenotypes are not well understood. Although the appearance of new lesions can represent initial hemorrhage into an already existent but undetected lesion, another possible explanation is that a second hit in an area of genetically predisposed vasculature gives rise to the development of hemorrhages and the typical appearance of CCMs.<sup>25</sup> Radiotherapy and dural sinus obstruction were found to be the predisposing factors for new lesions.<sup>7,10</sup> The hypothesis that a neoplasticlike process might be involved in the genesis of new lesions was also supported by some reports of new lesions occurring under hormonal influence during pregnancy<sup>7</sup> and the apparent seeding of a lesion along a biopsy track.<sup>33</sup> Recent studies have clarified that 2 main angiogenic factors, ie, VEGFs and their endothelial cell-specific protein tyrosine kinase receptors, mediate various facets of blood vessel formation during vasculogenesis.<sup>17,34</sup> The VEGFs and their receptors are usually down-regulated after birth, except under some physiologic or pathologic conditions.<sup>11</sup> Some immunohistochemical studies have focused on the proliferation of cavernomas and the expression of angiogenic growth factors.<sup>35-37</sup> The expression of proliferating cell nuclear antigen was detected in the endothelium of cavernomas, indicating growth potential in these lesions<sup>35</sup>; the expression of VEGF was diffusely increased, and this correlated with the recurrence of cerebrovascular malformations.<sup>11,36</sup>

In the present study, the expression of VEGF was much increased in type III lesions, without apparent recent hemorrhage, and serum VEGF level was higher than those of normal controls and subjects with hypertensive pontine ICH. Furthermore, VEGF level correlated well with the patterns of CCMs on brain MR images. Although it is not clear whether the expression of VEGF occurs as a result of a nonspecific pathologic response to intracranial hemorrhage or ischemia in various lesions, or whether it occurs in only truly proliferative lesions, our report demonstrates that CCMs can be progressive and highly dynamic because of the presence of as yet undetermined mediating factors, and VEGF may be one of these factors. Further research should assess serial serum VEGF levels in healthy control subjects, subjects with ICH of various causes, and subjects with ICH related to CCMs.

The clinical features, MR imaging patterns, and VEGF levels in our patient were stabilized by glucocorticoid treatment. Glucocorticoids have been found to have suppressive effects on the expression of VEGF or transforming growth factor.<sup>37,38</sup> We assume that glucocorticoids might influence the behavior of CCMs through the down-regulation of VEGF. Surgical intervention is not practical in cases of familial CCMs with multiple lesions. Further research should lead to a greater understanding of the molecular mechanisms mediating abnormal vasculogenesis in CCMs, and such understanding might lead to novel strategies for the therapeutic alteration of CCMs.

Cerebral cavernous malformations can show a highly dynamic course, and their biological activities are likely to be correlated with VEGF. We speculate that endothelial proliferation induced by VEGF is an important element in the underlying developmental and pathogenetic mechanisms of CCMs.

# Accepted for publication May 27, 2003.

Author contributions: Study concept and design (Drs Jung, Chu, Jeong, Bae, and Yoon); acquisition of data (Drs Jung, Park, and Yoon); analysis and interpretation of data (Drs Jung, Chu, and Yoon); drafting of the manuscript (Drs Jung, Jeong, and Park); critical revision of the manuscript for important intellectual content (Drs Jung, Chu, Jeong, Bae, and Yoon); statistical expertise (Drs Jung and Chu); study supervision (Dr Yoon).

Drs Jung and Chu contributed equally to this study.

Corresponding author and reprints: Byung-Woo Yoon, MD, PhD, Department of Neurology, Seoul National University Hospital, 28, Yongon-Dong, Chongro-Gu, 110-744, Seoul, South Korea (e-mail: bwyoon@snu.ac.kr).

#### REFERENCES

- Labauge P, Brunereau L, Levy C, Laberge S, Houtteville JP. The natural history of familial cerebral cavernomas: a retrospective MRI study of 40 patients. *Neuroradiology*. 2000;42:327-332.
- Meixensberger J, Hofmann E, Roosen K. Cerebral cavernomas: clinical aspects and therapy. Wien Med Wochenschr. 1997;147:194-198.
- Rigamonti D, Hadley MN, Drayer BP, et al. Cerebral cavernous malformations: incidence and familial occurrence. N Engl J Med. 1988;319:343-347.
- Bertalanffy H, Gilsbach JM, Eggert HR, Seeger W. Microsurgery of deep-seated cavernous angiomas: report of 26 cases. *Acta Neurochir (Wien)*. 1991;108:91-99.
- Siegel AM. Familial cavernous angioma: an unknown, known disease. Acta Neurol Scand. 1998;98:369-371.
- Spetzler RF, Wilson CB. Enlargement of an arteriovenous malformation documented by angiography: case report. J Neurosurg. 1975;43:767-769.
- Pozzati E, Acciarri N, Tognetti F, Marliani F, Giangaspero F. Growth, subsequent bleeding, and de novo appearance of cerebral cavernous angiomas. *Neurosur*gery. 1996;38:662-670.
- Houtteville JP. Brain cavernoma: a dynamic lesion. Surg Neurol. 1997;48:610-614.
- Detweiler PW, Porter RW, Zabramski JM, Spetzler RF. De novo formation of a central nervous system cavernous malformation: implications for predicting risk of hemorrhage: case report and review of the literature. *J Neurosurg.* 1997;87: 629-632.
- Challa VR, Moody DM, Brown WR. Vascular malformations of the central nervous system. J Neuropathol Exp Neurol. 1995;54:609-621.
- Uranishi R, Baev NI, Ng PY, Kim JH, Awad IA. Expression of endothelial cell angiogenesis receptors in human cerebrovascular malformations. *Neurosurgery*. 2001;48:359-368.
- Kim DE, Bae HJ, Lee SH, Kim H, Yoon BW, Roh JK. Gradient echo magnetic resonance imaging in the prediction of hemorrhagic vs ischemic stroke. *Arch Neu*rol. 2002;59:425-429.
- Chu K, Kang DW, Kim DE, Park SH, Roh JK. Diffusion-weighted and gradientecho MR findings of hemichorea-hemiballism associated with nonketotic hyperglycemia: a hyperviscosity syndrome? *Arch Neurol.* 2002;59:448-452.
- Zambramski JM, Wascher TM, Spetzler RF, et al. The natural history of familial cavernous malformations: results of an ongoing study. *J Neurosurg.* 1994;80: 422-432.

- Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. *Kidney Int.* 1999;56:794-814.
- Zhang ZG, Zhang L, Jiang Q, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. *J Clin Invest.* 2000;106:829-838.
- Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. *Proc Natl Acad Sci U S A*. 1998;95:15809-15814.
- Marti HH, Bernaudin M, Bellail A, et al. Hypoxia-induced vascular endothelial growth factor: expression precedes neovascularization after cerebral ischemia. Am J Pathol. 2000;156:965-976.
- Russell DS, Rubenstein LJ. Pathology of Tumors of the Nervous System. 5th ed. Baltimore, Md: Williams & Wilkins; 1989:730-736.
- Kattapong VJ, Hart BL, Davis LE. Familial cerebral cavernous angiomas: clinical and radiologic studies. *Neurology*. 1995;45:492-497.
- Labauge O, Enjolras O, Bonerandi JJ, et al. An association between autosomal dominant cerebral cavernomas and a distinctive hyperkeratotic cutaneous vascular malformation in 4 families. *Ann Neurol.* 1999;45:250-254.
- Robinson JR, Awad IA, Little JR. Natural history of the cavernous angioma. J Neurosurg. 1991;75:709-714.
- Sure U, Butz N, Schlegel J, et al. Endothelial proliferation, neoangiogenesis, and potential de novo generation of cerebrovascular malformations. *J Neurosurg*. 2001; 94:972-977.
- Del Curling O Jr, Kelly DL Jr, Elster AD, Craven TE. An analysis of the natural history of cavernous angiomas. J Neurosurg. 1991;75:702-708.
- Clatterbuck RE, Moriarty JL, Elmaci I, Lee RR, Breiter SN, Rigamonti D. Dynamic nature of cavernous malformations: a prospective magnetic resonance imaging study with volumetric analysis. *J Neurosurg.* 2000;93:981-986.
- Aiba T, Tanaka R, Koike T, Kameyama S, Takeda N, Komata T. Natural history of intracranial cavernous malformations. J Neurosurg. 1995;83:56-59.
- Kondziolka D, Lunsford LD, Kestle JRW. The natural history of cerebral cavernous malformations. J Neurosurg. 1995;83:820-824.
- Kim DS, Park YG, Choi JU, Chung SS, Lee KC. An analysis of the natural history of cavernous malformations. *Surg Neurol.* 1997;48:9-17.
- Moriarty JL, Clatterbuck RE, Rigamonti D. The natural history of cavernous malformations. *Neurosurg Clin N Am.* 1999;10:411-417.
- Porter PJ, Willinsky RA, Harper W, Wallace MC. Cerebral cavernous malformations: natural history and prognosis after clinical deterioration with or without hemorrhage. J Neurosurg. 1997;87:190-197.
- Labauge P, Brunereau L, Laberge S, Houtteville JP. Prospective follow-up of 33 asymptomatic patients with familial cerebral cavernous malformations. *Neurol*ogy. 2001;57:1825-1828.
- Mason I, Aase JM, Orrison WW, Wicks JD, Seigel RS, Bicknell JM. Familial cavernous angiomas of the brain in a Hispanic family. *Neurology*. 1988;38:324-326.
- Ogilvy CS, Moayeri N, Golden JA. Appearance of a cavernous hemangioma in the cerebral cortex after a biopsy of a deeper lesion. *Neurosurgery*. 1993;33: 307-309.
- Monacci WT, Merrill MJ, Oldfield EH. Expression of vascular permeability factor/ vascular endothelial growth factor in normal rat tissues. *Am J Physiol*. 1993; 264(4, pt 1):C995-C1002.
- Notelet L, Houttenille JP, Khoury S, Lechevalier B, Chapon F. Proliferating cell nuclear antigen (PCNA) in cerebral cavernomas: an immunocytochemical study of 42 cases. *Surg Neurol.* 1997;47:364-370.
- Sonstein WJ, Kader A, Michelsen WJ, Llena JF, Hirano A, Casper D. Expression of vascular endothelial growth factor in pediatric and adult cerebral arteriovenous malformations: an immunocytochemical study. *J Neurosurg.* 1996;85:838-845.
- Machein MR, Kullmer J, Ronicke V, et al. Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic fat glioma cells. *Neuropathol Appl Neurobiol*. 1999;25:104-112.
- Nauck M, Darakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. *Eur J Pharmacol.* 1998;341:309-315.